No Data
No Data
Cancer Research Sees Major Boost as New Breakthroughs Emerge From Key Oncology Players
JonesTrading Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $137
Buy Rating Reaffirmed for Lantheus Holdings Amid Promising PNT2002 Trial Results
TD Cowen Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $145
Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating
Truist Financial Issues a Buy Rating on Lantheus (LNTH)
No Data
No Data